Skip to content
Medical Health Aged Care

First proof that activation of receptors involved in the gut microbial breakdown of fibre cuts cardiovascular disease risk by 20 per cent

Monash University 2 mins read

A Monash University study of almost 400,000 people, published in the journal Cardiovascular Research, is the first to indicate, in humans, that the signalling of substances called short-chain fatty acids or SCFAs, released when gut bacteria break down dietary fibre, significantly protects against cardiovascular disease and hypertension by up to 20 per cent.  

A previous clinical trial by the Monash team, led by Professor Francine Marques, has shown that these SCFAs – when provided as a supplement – leads to lowered blood pressure. Another trial is underway (https://marqueslab.com/trials).

The current study used data from the UK Biobank database and found rare genetic variants that profoundly impact the function of receptors that bind to SCFAs essentially prevent people from utilising the cardiovascular-protection offered by their own gut microbes.

“We wanted to determine whether people with these genetic modifications had an increased risk of hypertension and major adverse cardiac events, including acute coronary syndrome, heart failure, and ischemic stroke,” said Professor Marques.

For this, the researchers compared individuals with these genetic variants and their cardiovascular medical history to controls, finding that this affected cohort had a significantly higher incidence of hypertension and long-term risk of cardiovascular disease, including heart attacks, heart failure and stroke.

Dr Leticia Camargo Tavares was the leading author of the study.

“The study found that disruption in these receptors is associated with up to 20 per cent increased prevalence of hypertension and heart disease or stroke – even after accounting for other risk factors like body weight and smoking,” Dr Tavares said.

“However, it is worth mentioning these rare genetic variants occur in less than 1 per cent of individuals,” Professor Marques said.

Importantly, the researchers also looked into what happened to this affected cohort – without the cardioprotective capacity – when fibre intake followed dietary guidelines. “If they consumed adequate dietary fibre, but were unable to turn this into protection against heart disease, then this would prove the importance of short-chain fatty acids signalling in cardio-protection,” Professor Marques said.

“Consistent with our hypothesis, the prevalence of hypertension was significantly higher in this cohort, even among those who ate a diet rich in fibre,” Dr Tavares added.

The research team is currently in the process of developing a commercially available product that can deliver SCFAs orally. In addition, the team aims to develop drugs that activate these receptors, which may provide a novel way to lower blood pressure and prevent heart disease. 

Read the full paper in Cardiovascular Research: Rare pathogenic variants in G-protein-coupled receptor genes involved in gut-to-host communication are associated with cardiovascular disease risk. DOI: 10.1093/cvr/cvaf070

 

For media enquiries please contact:

Monash University

Tania Ewing Media and Communications Contractor
E: [email protected] 

T: +61 (0) 408 378 422

For more Monash media stories, visit our news and events site  


For general media enquiries please contact:
Monash Media
E: [email protected]
T: +61 (0) 3 9903 4840

More from this category

  • Medical Health Aged Care
  • 18/03/2026
  • 18:41
Samsung Bioepis Co., Ltd.

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of KoreaSamsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology   INCHEON, Korea--BUSINESS WIRE-- Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The…

  • Contains:
  • Medical Health Aged Care
  • 18/03/2026
  • 16:49
Palliative Care Australia

Better end-of-life care for older Australians must be the next step in aged care reform

Palliative Care Australia this week brought leaders from aged care, palliative care, health, advocacy, research and policy together in Melbourne for its inauguralPalliative Care…

  • Contains:
  • Indigenous, Medical Health Aged Care
  • 18/03/2026
  • 07:21
Australian and New Zealand Journal of Public Health / Public Health Association of Australia

Emerging Aboriginal leaders call for greater Indigenous control over native foods

As Australia’s native food industry booms, experts say Indigenous people must have a seat at the table Aboriginal leaders and advocates have joined together today to call out commercial companies exploiting native food knowledge without adequate community engagement. They are urging government action to ensure Indigenous people can better lead and control the access and benefits that arise from their traditional foods and knowledge. The new evidence-based commentary, published in the Australian and New Zealand Journal of Public Health, represents the collective view of six leading Aboriginal academics and one non-Indigenous researcher with expertise across bush food, traditional Indigenous medicines,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.